EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY-NC-ND 4.0

Effect of Itraconazole, a CYP3A4 Inhibitor, and Rifampin, a CYP3A4 Inducer, on the Pharmacokinetics of Vatiquinone

Lucy Lee, Martin Thoolen, Jiyuan Ma, Diksha Kaushik, Lee Golden, Ronald Kong

Clinical Pharmacology in Drug Development · 2024

DOI: 10.1002/cpdd.1461 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Clinical Pharmacology in Drug Development, 2024. Verfasst von Lucy Lee und 5 weiteren Autor:innen. Beteiligte Einrichtung: PTC Therapeutics, Inc., Warren, NJ, USA. Hauptthemen laut MEDLINE: Itraconazole, Rifampin, Cytochrome P-450 CYP3A Inducers, Drug Interactions. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 11 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Vatiquinone is a small molecule inhibitor of 15‐lipoxygenase in development for patients with Friedreich's ataxia. The objective of this analysis was to determine the effect of a cytochrome P450 isoform 3A4 (CYP3A4) inhibitor and inducer on vatiquinone pharmacokinetics (PKs). The coadministration of 400 mg of vatiquinone with 200 mg of itraconazole (a CYP3A4 inhibitor) resulted in increased maximum observed concentration (C max ) of vatiquinone and systemic exposure (AUC 0‐inf ) by approximately 3.5‐ and 2.9‐fold, respectively. The coadministration of 400 mg of vatiquinone with 600 mg of rifampin (a CYP3A4 inducer) resulted in decreased vatiquinone C max and AUC 0‐inf by approximately 0.64‐ and 0.54‐fold, respectively. The terminal half‐life of vatiquinone was not affected by itraconazole or rifampin. These clinical study results confirm the in vitro reaction phenotyping data that shows that CYP3A4 plays an important role in vatiquinone metabolism. The result of this analysis together with phase 3 efficacy and safety data, population PK analysis, and the exposure‐response relationship will determine if the extent of vatiquinone changes in the presence of CYP3A4 inhibitors and inducers are considered clinically relevant.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ItraconazoleRifampinCytochrome P-450 CYP3A InducersDrug InteractionsCytochrome P-450 CYP3A InhibitorsArea Under CurveHumansAdultMaleFemaleYoung AdultCytochrome P-450 CYP3AMiddle AgedHalf-LifeQuinones

Stichwörter der Autor:innen

drug‐drug interactionhealthy volunteersitraconazolerare diseaserifampin

Substanzen

ItraconazoleRifampinCytochrome P-450 CYP3A InducersCytochrome P-450 CYP3A InhibitorsCytochrome P-450 CYP3ACYP3A4 protein, humanQuinones

Autor:innen und Institutionen

  • PTC Therapeutics, Inc., Warren, NJ, USA.

Zitieren

APA

Lee, L., Thoolen, M., Ma, J., Kaushik, D., Golden, L., & Kong, R. (2024). Effect of Itraconazole, a CYP3A4 Inhibitor, and Rifampin, a CYP3A4 Inducer, on the Pharmacokinetics of Vatiquinone. Clinical Pharmacology in Drug Development. https://doi.org/10.1002/cpdd.1461

Vancouver

Lee L, Thoolen M, Ma J, Kaushik D, Golden L, Kong R. Effect of Itraconazole, a CYP3A4 Inhibitor, and Rifampin, a CYP3A4 Inducer, on the Pharmacokinetics of Vatiquinone. Clinical Pharmacology in Drug Development. 2024. doi:10.1002/cpdd.1461

BibTeX
@article{Lee2024,
  author = {Lee, Lucy and Thoolen, Martin and Ma, Jiyuan and Kaushik, Diksha and Golden, Lee and Kong, Ronald},
  title = {Effect of Itraconazole, a CYP3A4 Inhibitor, and Rifampin, a CYP3A4 Inducer, on the Pharmacokinetics of Vatiquinone},
  journal = {Clinical Pharmacology in Drug Development},
  year = {2024},
  doi = {10.1002/cpdd.1461}
}
Kostenlos starten →